Novartis ($NVS) is whacking support jobs in its pharmaceutical division but said it is adding elsewhere, including in over-the-counter manufacturing and supply chain, so that the company's head count in Switzerland will remain unchanged at about 15,000, Reuters reports. The changes are needed to help with new product launches. The drugmaker last year said it would invest €60 million ($78.6 million) to expand OTC manufacturing at a plant in Prangins, Switzerland, that it previously had planned to close. It will invest another €90 million ($118 million) by 2020, with plans to boosts its capacity by 70% in the next 10 years, feeding Novartis' growing emphasis on OTC products. Story | More